Why ? do you think it will go higher soon ?
Dumped at .145..TY stock God's...In .0919
You may as well unload now...geez.. what a fiasco
And in the case of IPIX like it is here with Galera, the FDA constantly wants more testing and more testing. But yet for an experimental MRNA shot which scientists and the medical community will not truly know the effects for another 5 years on one’s health, they green light. In my opinion, it’s all about who greases whose palms!!!
Overreaction??? This looks to be going down the route of IPIX. Both of these companies Galera and Innovation Pharma had a product for OM and both of them have been rejected by the FDA. It’s amazing to me the stupidity of how it goes especially since they have nothing that really works right now and patients that develop OM usually have to stop cancer treatments and then decide whether or not to continue once the symptoms subside and heal. And the cost for a severe OM patient to be treated is very, very expensive.
Not bad??? Check out market reaction. Down 50% pre market.
It is possible to fill that $2 gap Omega... Depends on how good the news is...
Early Christmas 🎄
Gap fill would be excellent.
fda news run to $2 tomorrow??
Yep, I think that it's leaking out that news is coming. Maybe this afternoon or tomorrow???
Think we have seen the bottom...Looking better here
What’s the intended date?
$GRTX According to the FDA guidance document titled “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry”, after a Type A meeting, the FDA will provide written feedback to the sponsor or applicant within 14 calendar days of the meeting. This feedback will include a summary of the meeting, any agreements reached during the meeting, and any action items that need to be addressed by either party.
Agreements that could be reached during a Type A meeting include:
Agreement on clinical trial design: The FDA may agree to a sponsor’s or applicant’s proposed clinical trial design.
Agreement on endpoints: The FDA may agree to a sponsor’s or applicant’s proposed endpoints for a clinical trial.
Agreement on statistical analysis: The FDA may agree to a sponsor’s or applicant’s proposed statistical analysis plan for a clinical trial.
Agreement on labeling: The FDA may agree to a sponsor’s or applicant’s proposed labeling for a drug product.
Give it 10 minutes
Sent an email to co., but no reply yet.
Yep between the company selling shares and shorts u can't win with BIO's... just be ready to sell the spikes and i fucked up yesterday early... about all gone now...
...or the result of complete silence.
we see an sell off here ??????time will tell
GRTX: Personally, I think there is just a lot of folks holding and are in a waiting pattern. Unfortunately, that allows the shorts to do their thing and keep it down and take it lower.
The flip side of that is, with the right pressure, they'll be the ones Buying, just to stop the bleeding.
This week brings the 30days to an end.
Holding and added some this morning from INVO profits.
(I'm not one for "averaging down", just adding and as luck would have it, the price is lower than I started in at.)
surprising that GRTX trading red.
GRTX: The FDA is expected to issue written meeting minutes approximately 30 days following the meeting.
GRTX: Should not be any dilution for a while. >>>>>>>>>
As of June 30, 2023, Galera had cash, cash equivalents and short-term investments of $38.8 million. Galera expects that its existing cash, cash equivalents and short-term investments, taking into account the implementation of the reduction in workforce announced in August 2023, will enable Galera to fund its operating expenses and capital expenditure requirements into the second quarter of 2024.